
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
12 AUGUST ? After its fastest review yet for a cancer drug, FDA has approved the colorectal cancer drug Eloxatin (oxaliplatin).
Colorectal Cancer Drug Approved on 'Fast Track'—After its fastest review yet for a cancer drug, FDA has approved thecolorectal cancer drug Eloxatin (oxaliplatin). Used in combination withother cancer drugs, the drug was shown to shrink tumors in some patients anddelay resumed tumor growth.http://www.fda.gov/bbs/topics/NEWS/2002/NEW00825.html






